[ad_1]
<div innerhtml = "
BAN2401 is based on the so-called amyloid hypothesis, which states that toxic deposits in the brain, called plaques, are responsible for the destruction of memory. ] Biogen developed the drug to eradicate clusters of free-flowing cells that fold into plaques. In this way, their accumulation must be prevented and the progression of the disease theoretically delayed.
The study included approximately 900 patients with Alzheimer's Disease in their early stages. The developers suggested that the drug would be useful after about a year of treatment. In December, companies admitted a failure. However, they continued to study patients and to monitor the effect of
BAN2401 . After 18 months, he actually showed effects.
Some open questions
Patients in the high-dose group experienced significant cognitive improvement in six months compared to placebo [Kramer] . Nevertheless, unanswered questions remain. For example, how many patients in this group were cognitive enhancers – companies use their own tests, not those that are commonly used in Alzheimer's trials.
Despite many ambiguities, the results of the study give hope, especially in a year when researchers suffered a few setbacks (read more here …). The pharmaceutical company
Pfizer was even withdrawn early in the year entirely from Alzheimer 's research.
">
BAN2401 is based on the so-called amyloid hypothesis, which states that toxic deposits in the brain called plaques are responsible for the destruction of memory.
Biogen developed the drug to eradicate clusters of free-flowing cells that fold into plaques. In this way, their accumulation must be prevented and the progression of the disease theoretically delayed.
The study included approximately 900 patients with Alzheimer's Disease in their early stages. The developers suggested that the drug would be useful after about a year of treatment. In December, companies admitted a failure. However, they continued to study patients and to monitor the effect of
BAN2401 . After 18 months, he actually showed effects.
Some open questions
Patients in the high-dose group experienced significant cognitive improvement in six months compared to placebo [Kramer] . Nevertheless, unanswered questions remain. For example, how many patients in this group were cognitive enhancers – companies use their own tests, not those that are commonly used in Alzheimer's trials.
Despite many ambiguities, the results of the study give hope, especially in a year when researchers suffered a few setbacks (read more here …). The pharmaceutical company
Pfizer was even withdrawn early in the year entirely from Alzheimer 's research.
